N,N-二甲基吡咯烷-3-胺双盐酸盐 | 50534-42-4

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 中文名称: N,N-二甲基吡咯烷-3-胺双盐酸盐
• 中文别名: 六水合三(2,2-联吡啶)氯化钌；3-(二甲基氨基)吡咯烷二盐酸盐；稻瘟灵；4-二乙基氨基哌啶二盐酸盐；3-(二甲胺基)吡咯烷双盐酸盐
• 英文名称: N,N-dimethylpyrrolidin-3-amine dihydrochloride
• 英文别名: N,N-dimethylpyrrolidin-3-amine;dihydrochloride
• CAS: 50534-42-4
• 化学式: C6H16Cl2N2
• 分子量: 187.11
• InChiKey: LCPKWRSLMCUOOZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.75
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  15.3
• 氢给体数：
  3
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P280,P305+P351+P338,P310
• 危险性描述：
  H302,H315,H319,H332,H335

文献信息

• [EN] 1,3,4-OXADIAZOLE SULFONAMIDE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME<br/>[FR] COMPOSÉS DÉRIVÉS DE 1,3,4-OXADIAZOLE SULFONAMIDE SERVANT D'INHIBITEUR DE L'HISTONE DÉSACÉTYLASE 6, ET COMPOSITION PHARMACEUTIQUE COMPRENANT CEUX-CI
  申请人：CHONG KUN DANG PHARMACEUTICAL CORP

  公开号：WO2017018803A1

  公开（公告）日：2017-02-02

  The present invention relates to novel compounds represented by the formula I having histone deacetylase 6 (HDAC6) inhibitory activity, stereoisomers thereof or pharmaceutically acceptable salts thereof, the use thereof for the preparation of therapeutic medicaments, pharmaceutical compositions containing the same, a method for treating diseases using the composition, and methods for preparing the novel compounds. (I) The novel compounds, stereoisomers thereof or pharmaceutically acceptable salts thereof according to the present invention have histone deacetylase (HDAC) inhibitory activity and are effective for the prevention or treatment of HDAC6-mediated diseases.

  本发明涉及具有组蛋白去乙酰化酶6（HDAC6）抑制活性的新化合物，其立体异构体或药学上可接受的盐，其用于制备治疗药物，含有相同化合物的药物组合物，使用该组合物治疗疾病的方法，以及制备新化合物的方法。根据本发明，这些新化合物、其立体异构体或药学上可接受的盐具有组蛋白去乙酰化酶（HDAC）抑制活性，并且对于预防或治疗HDAC6介导的疾病有效。
• IMIDAZO[4,5-C]QUINOLINE COMPOUNDS AND THEIR USE AS ATM KINASE INHIBITORS
  申请人：Deutsches Krebsforschungszentrum

  公开号：EP3992191A1

  公开（公告）日：2022-05-04

  The present invention relates to imidazo[4,5-c]quinoline compounds and to their use in the inhibition, regulation and/or modulation of signal transduction by ATM kinase and, in particular, for the treatment of ATM mediated diseases, especially cancer.

  本发明涉及咪唑[4,5-c]喹啉化合物及其在ATM激酶信号转导的抑制、调节和/或调节中的使用，特别是用于治疗ATM介导的疾病，尤其是癌症。
• Optical active 1,4-dihydropyridine compounds as bradykinin antagonists
  申请人：PFIZER INC.

  公开号：EP0899261A1

  公开（公告）日：1999-03-03

  This invention provides a compound of the formula (I): and its pharmaceutically acceptable salts, wherein A1 and A2 are each halo; R1 and R2 are independently C1-4 alkyl; R3 is substituted or unsubstituted, phenyl or naphthyl; Y is heterocyclic group selected from C5-10 azacycloalkyl, C6-10 diazacycloalkyl, C7-10 azabicycloalkyl and the like; and R4 is selected from (a) substituted or unsubstituted C1-8 alkyll; (b) substituted or unsubstituted amino; (c) substituted or unsubstituted C2-6 alkanoyl; (d) substituted or unsubstituted C3-8 cycloalkyl or C7-14 bicycloalkyl; (e) substituted or unsubstituted C5-10 azacycloalkyl or C6-10 diazacycloalkyl, and (f) substituted or unsubstituted C7-14 mono- or di-azabicycloalkyl. These compounds are useful for the treatment of medical conditions caused by bradykinin such as inflammation, cardiovascular disease, pain, etc. This invention also provides a pharmaceutical composition comprising the above compound, and intermediates of the above compounds.

  本发明提供了一种式（I）化合物： 及其药学上可接受的盐类，其中 A1 和 A2 各为卤代；R1 和 R2 独立地为 C1-4 烷基；R3 为取代或未取代的苯基或萘基；Y 为杂环基团，选自 C5-10 氮杂环烷基、C6-10 二氮杂环烷基、C7-10 氮杂双环烷基等；R4 选自 (a) 取代或未取代的 C1-8 烷基；(b) 取代或未取代的氨基； (c) 取代或未取代的 C2-6 烷酰基； (d) 取代或未取代的 C3-8 环烷基或 C7-14 双环烷基； (e) 取代或未取代的 C5-10 氮杂环烷基或 C6-10 二氮杂环烷基，以及 (f) 取代或未取代的 C7-14 单氮杂双环烷基或双氮杂双环烷基。这些化合物可用于治疗由缓激肽引起的病症，如炎症、心血管疾病、疼痛等。本发明还提供了一种药物组合物，其中包含上述化合物以及上述化合物的中间体。
• 1,3,4-OXADIAZOLE SULFONAMIDE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
  申请人：Chong Kun Dang Pharmaceutical Corp.

  公开号：EP3328843A1

  公开（公告）日：2018-06-06
• INHIBITORS OF BTK AND MUTANTS THEREOF
  申请人：Newave Pharmaceutical Inc.

  公开号：EP3755702A1

  公开（公告）日：2020-12-30